Anavex Life Sciences Corp (AVXL)

[boi568]

How would the FDA justify using amyloid plaque reduction as a biomarker, which is sometimes present in healthy individuals and is now being acknowledged as symptomatic instead of causative, yet reject as a biomarker excessive brain shrinkage -- clearly causative in AD and not present in healthy individuals? Brain shrinkage is certainly analogous as a biomarker to tumor size in cancers, which are obvious biomarkers.

Excuse my usage here, but accepting a reduction in excessive brain shrinkage as a new AD biomarker is a no brainer.